Drug Profile
XmAb 698
Alternative Names: AMG-424; CD38 x CD3 - Xencor; CD38 x CD3 bispecific antibody - Xencor; XmAb-18968; XmAb-698; XmAb-968Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 09 Dec 2023 Updated efficacy data from a phase I trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from a phase I trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 04 Dec 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) before December 2023 (Xencor pipeline, December 2023)